Oppenheimer upgrades Alnylam to Outperform on Amvuttra launch

Oppenheimer analyst Leland Gershell upgraded Alnylam (ALNY) to Outperform from Perform with a $490 price target The first full quarter of Amvuttra sales in transthyretin amyloid cardiomyopathy sales beat by a sizable margin as Alnylam secured payer agreements much faster than anticipated, the analyst tells investors in a research note. The firm says management commentary on the earnings was favorable on all aspects of the launch. Oppenheimer expects further share outperformance as Amvuttra’s commercialization for ATTR-CM continues and Street estimates move up.